CN115884977A - 立体选择性制备选择的嘌呤氨基磷酸酯 - Google Patents

立体选择性制备选择的嘌呤氨基磷酸酯 Download PDF

Info

Publication number
CN115884977A
CN115884977A CN202180051015.9A CN202180051015A CN115884977A CN 115884977 A CN115884977 A CN 115884977A CN 202180051015 A CN202180051015 A CN 202180051015A CN 115884977 A CN115884977 A CN 115884977A
Authority
CN
China
Prior art keywords
compound
formula
alkyl
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051015.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·莫萨
N·乔杜里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atea Pharmaceuticals Inc
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of CN115884977A publication Critical patent/CN115884977A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Luminescent Compositions (AREA)
CN202180051015.9A 2020-08-19 2021-08-19 立体选择性制备选择的嘌呤氨基磷酸酯 Pending CN115884977A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063067726P 2020-08-19 2020-08-19
US63/067,726 2020-08-19
US202063074302P 2020-09-03 2020-09-03
US63/074,302 2020-09-03
US202063094759P 2020-10-21 2020-10-21
US63/094,759 2020-10-21
US202063129306P 2020-12-22 2020-12-22
US63/129,306 2020-12-22
PCT/US2021/046778 WO2022040473A1 (en) 2020-08-19 2021-08-19 Stereoselective manufacture of selected purine phosphoramidates

Publications (1)

Publication Number Publication Date
CN115884977A true CN115884977A (zh) 2023-03-31

Family

ID=80323295

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051015.9A Pending CN115884977A (zh) 2020-08-19 2021-08-19 立体选择性制备选择的嘌呤氨基磷酸酯

Country Status (9)

Country Link
US (1) US20230331751A1 (cg-RX-API-DMAC7.html)
EP (1) EP4200309A4 (cg-RX-API-DMAC7.html)
JP (2) JP7851034B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230053640A (cg-RX-API-DMAC7.html)
CN (1) CN115884977A (cg-RX-API-DMAC7.html)
AU (1) AU2021327241A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173661A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002064A (cg-RX-API-DMAC7.html)
WO (1) WO2022040473A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117886872A (zh) * 2021-12-15 2024-04-16 南京知和医药科技有限公司 一种抗病毒感染的嘌呤核苷衍生物及其药物组合物和用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2022291927A1 (en) 2021-06-17 2024-01-04 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CN121628124B (zh) * 2026-02-05 2026-04-10 山东鲁源化工科技有限公司 一种高热稳定性聚磷酸酯阻燃剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104583224A (zh) * 2012-07-03 2015-04-29 百时美施贵宝公司 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法
CN107427530A (zh) * 2015-03-06 2017-12-01 阿堤亚制药公司 用于HCV治疗的β‑D‑2’‑脱氧‑2’α‑氟‑2’‑β‑C‑取代的‑2‑改性的‑N6‑取代的嘌呤核苷酸
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3512863T (pt) * 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
WO2021173713A1 (en) * 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104583224A (zh) * 2012-07-03 2015-04-29 百时美施贵宝公司 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法
CN107427530A (zh) * 2015-03-06 2017-12-01 阿堤亚制药公司 用于HCV治疗的β‑D‑2’‑脱氧‑2’α‑氟‑2’‑β‑C‑取代的‑2‑改性的‑N6‑取代的嘌呤核苷酸
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113784721A (zh) * 2020-02-27 2021-12-10 阿堤亚制药公司 抗covid-19的高活性化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARDY ET AL.: "Treating a Global Health Crisis with a Dose of Synthetic Chemistry", ACS CEMTRAL SCIENCE, 30 June 2020 (2020-06-30), pages 1017 - 1030 *
KRISTY TRAN ET AL.: "Development of a Diastereoselective Phosphorylation of a Comple Nucleoside via Dynamic Kinetic Resolution", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 80, 3 April 2015 (2015-04-03), pages 4994 - 5003 *
KRISTY TRAN ET AL.: "Development of a Diastereoselective Phosphorylation of a Complex Nucleoside via Dynamic Kinetic Resolution", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 80, 3 April 2015 (2015-04-03), pages 4994 - 5003 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117886872A (zh) * 2021-12-15 2024-04-16 南京知和医药科技有限公司 一种抗病毒感染的嘌呤核苷衍生物及其药物组合物和用途

Also Published As

Publication number Publication date
JP7851034B2 (ja) 2026-04-24
JP2023538594A (ja) 2023-09-08
US20230331751A1 (en) 2023-10-19
JP2026117077A (ja) 2026-07-14
AU2021327241A1 (en) 2023-04-20
TW202214260A (zh) 2022-04-16
MX2023002064A (es) 2023-03-16
KR20230053640A (ko) 2023-04-21
EP4200309A1 (en) 2023-06-28
EP4200309A4 (en) 2025-03-19
CA3173661A1 (en) 2022-02-24
WO2022040473A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
US20230331751A1 (en) Stereoselective manufacture of selected purine phosphoramidates
AU2021290235B2 (en) Chiral reagents for preparation of homogeneous oligomers
AU2009207297B2 (en) Novel heterocyclic compounds
JP2025509663A (ja) 置換スピロオキシインドール誘導体を調製するための方法
CA2934531C (en) Process methods for phosphatidylinositol 3-kinase inhibitors
WO2009014730A1 (en) Macrocyclic serine protease inhibitors
CZ20001744A3 (en) Aminothiazole inhibitors of cyclin-dependent kinases
ES2738211T3 (es) Procedimiento mejorado de preparación de profármacos a base de duocarmicina
CN104583224A (zh) 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法
CA3229692A1 (en) Quinazoline compounds for treatment of disease
CN116438160A (zh) 用于治疗病毒感染的氨基氨基甲酰基化合物
EP3458452B1 (en) Heterocyclic compounds useful as anti-bacterial agents and method for production
JP7533920B2 (ja) リン酸エステルの新規合成法
CN102924454B (zh) 恩替卡韦的合成方法
EP2625181B1 (en) Method of preparation of antiviral compounds and useful intermediates thereof
WO2025080631A1 (en) Process for making a kras g12c inhibitor
WO2017191608A1 (en) Novel process for preparation of idelalisib
CA3245127A1 (en) BIS-PROTECTED ACTIVATED GUANINE MONOMERS
CN102443032B (zh) 制备抗病毒组合物的方法及其中间体的应用
JP2024168691A (ja) 疑似固相保護基、それを用いたヌクレオシド保護体又はオリゴヌクレオチド保護体、オリゴアミダイト前駆体の製造方法
CZ20011145A3 (cs) Antivirové purinové deriváty a jejich použití

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination